研究揭示癌症患者感染SARS-CoV-2後的急性免疫特徵與長期影響
作者：
小柯機器人發布時間：2021/1/6 16:38:45
英國倫敦大學國王學院Sultan Abdul-Jawad等研究人員合作揭示癌症患者感染SARS-CoV-2後的急性免疫特徵與長期影響。這一研究成果於2021年1月4日在線發表在國際學術期刊《癌細胞》上。
鑑於免疫系統對於癌症監測和治療的重要性，研究人員分析了癌症患者可能會受到的SARS-CoV-2感染影響。在腫瘤類型、階段和治療的某些異質性中，暴露於病毒的實體癌患者顯示出SARS-CoV-2的主要影響，從其免疫特徵與COVID-19+非癌症患者的免疫特徵相似可明顯看出。血液學惡性腫瘤並非如此簡單，暴露於病毒的患者共同表現出異質的體液反應、耗竭的T細胞表型和高度流行的長時間病毒脫落。
此外，雖然恢復後的實體癌症患者的免疫表型與未接觸病毒的癌症患者相似，但恢復後的血液癌症患者顯示出獨特的、持久的免疫學影響。因此，雖然包括晚期癌症在內的實體癌症患者似乎沒有比一般人群更多地面臨SARS-CoV-2相關免疫失調的風險，但血液癌症患者顯示出SARS-CoV-2暴露的複雜免疫學後果，這可能有助於提供相關護理。
附：英文原文
Title: Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients
Author: Sultan Abdul-Jawad, Luca Baù, Thanussuyah Alaguthurai, Irene del Molino del Barrio, Adam G. Laing, Thomas S. Hayday, Leticia Monin, Miguel Munoz-Ruiz, Louisa McDonald, Isaac Francos Quijorna, Duncan McKenzie, Richard Davis, Anna Lorenc, Julie Nuo En Chan, Sarah Ryan, Eva Bugallo-Blanco, Rozalyn Yorke, Shraddha Kamdar, Matthew Fish, Iva Zlatareva, Pierre Vantourout, Aislinn Jennings, Sarah Gee, Katie Doores, Katharine Bailey, Sophie Hazell, Julien De Naurois, Charlotte Moss, Beth Russell, Aadil A. Khan, Mark Rowley, Reuben Benjamin, Deborah Enting, Doraid Alrifai, Yin Wu, You Zhou, Paul Barber, Tony Ng, James Spicer, Mieke Van Hemelrijck, Mayur Kumar, Jennifer Vidler, Yadanar Lwin, Paul Fields, Sophia N. Karagiannis, Anthony C.C. Coolen, Anne Rigg, Sophie Papa, Adrian C. Hayday, Piers E.M. Patten, Sheeba Irshad
Issue&Volume: 2021-01-04
Abstract: Given the immune system’s importance for cancer surveillance and treatment, we haveinvestigated how it may be affected by SARS-CoV-2 infection of cancer patients. Acrosssome heterogeneity in tumour type, stage and treatment, virus-exposed solid cancerpatients display a dominant impact of SARS-CoV-2, apparent from the resemblance oftheir immune signatures to those for COVID-19+ non-cancer patients. This is not the case for haematological malignancies, with virus-exposedpatients collectively displaying heterogeneous humoral responses, an exhausted T cellphenotype and a high prevalence of prolonged virus shedding. Furthermore, while recoveredsolid cancer patients』 immunophenotypes resemble those of non-virus-exposed cancerpatients, recovered haematological cancer patients display distinct, lingering immunologicallegacies. Thus, while solid cancer patients, including those with advanced disease,seem no more at risk of SARS-CoV-2-associated immune dysregulation than the generalpopulation, haematological cancer patients show complex immunological consequencesof SARS-CoV-2 exposure that might usefully inform their care.
DOI: 10.1016/j.ccell.2021.01.001
Source: https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00001-5